Laboratory of Molecular Immunogenetics of Cancer, Institute of Gene Biology RAS, 111394 Moscow, Russia.
Int J Mol Sci. 2022 May 20;23(10):5752. doi: 10.3390/ijms23105752.
An investigation of innate immunity receptors sheds light on the mechanisms of inflammation and associated immune reactions. One of the key immune regulators is the TREM-1 receptor, which is involved in both inflammation and antitumor immune response. In this article, we have obtained a new ligand for the TREM-1 receptor. The peptide, named N3, is a part of the innate immune protein PGLYRP1/Tag7. It is responsible for activating the TREM-1 signaling pathway. Here, we have demonstrated that the N3 peptide acts like other TREM-1 receptor ligands: its binding results in a mild inflammation response and appearance of cytotoxic lymphocytes. We have shown that cytotoxic populations of lymphocytes in N3 peptide-treated PBMCs are similar to those treated with Tag7 or Hsp70. We also determined the part of the N3 peptide responsible for binding to TREM-1. The resulting peptide (N9) consists of nine amino acids and can be considered as a potential peptide that blocks TREM-1 signaling.
固有免疫受体的研究揭示了炎症和相关免疫反应的机制。关键的免疫调节剂之一是 TREM-1 受体，它参与炎症和抗肿瘤免疫反应。在本文中，我们获得了 TREM-1 受体的新配体。该肽名为 N3，是先天免疫蛋白 PGLYRP1/Tag7 的一部分。它负责激活 TREM-1 信号通路。在这里，我们已经证明 N3 肽的作用类似于其他 TREM-1 受体配体：它的结合导致轻度炎症反应和细胞毒性淋巴细胞的出现。我们已经表明，在 N3 肽处理的 PBMC 中，细胞毒性淋巴细胞群与用 Tag7 或 Hsp70 处理的细胞毒性淋巴细胞群相似。我们还确定了与 TREM-1 结合的 N3 肽的部分。得到的肽（N9）由九个氨基酸组成，可被视为一种潜在的肽，可阻断 TREM-1 信号。
